QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:ALDX

Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis

$3.27
+0.19 (+6.17%)
(As of 05:21 PM ET)
Today's Range
$3.12
$3.50
50-Day Range
$2.77
$4.22
52-Week Range
$1.42
$11.97
Volume
857,632 shs
Average Volume
500,674 shs
Market Capitalization
$192.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.33

Aldeyra Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
280.7% Upside
$12.33 Price Target
Short Interest
Healthy
3.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Aldeyra Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$365,194 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.26) to ($0.43) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.95 out of 5 stars

Medical Sector

401st out of 938 stocks

Pharmaceutical Preparations Industry

186th out of 433 stocks

ALDX stock logo

About Aldeyra Therapeutics Stock (NASDAQ:ALDX)

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

ALDX Stock Price History

ALDX Stock News Headlines

Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Intellia Therapeutics, Inc.
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
BTIG Reaffirms Their Buy Rating on Aldeyra Therapeutics (ALDX)
Aldeyra stock jumps 8% on dermatitis drug updates
Lexington biotech gets second FDA rejection this year
See More Headlines
Receive ALDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/27/2021
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALDX
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.33
High Stock Price Target
$15.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+300.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-37,540,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.04 per share

Miscellaneous

Free Float
54,597,000
Market Cap
$181.41 million
Optionable
Optionable
Beta
1.53
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Todd C. Brady (Age 48)
    M.D., Ph.D., Chief Executive Officer and Director
  • Joshua Reed (Age 47)
    Chief Financial Officer
  • David McMullin (Age 45)
    Chief Commercial Officer
  • James A. Gow (Age 53)
    M.D., Senior Vice President of Clinical Development
  • Stephen G. Machatha (Age 43)
    Ph.D., Senior Vice President, Technical Operation

ALDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Aldeyra Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALDX shares.
View ALDX analyst ratings
or view top-rated stocks.

What is Aldeyra Therapeutics' stock price target for 2024?

3 equities research analysts have issued 1 year price targets for Aldeyra Therapeutics' stock. Their ALDX share price targets range from $8.00 to $15.00. On average, they expect the company's stock price to reach $12.33 in the next year. This suggests a possible upside of 280.7% from the stock's current price.
View analysts price targets for ALDX
or view top-rated stocks among Wall Street analysts.

How have ALDX shares performed in 2024?

Aldeyra Therapeutics' stock was trading at $3.51 at the beginning of the year. Since then, ALDX shares have decreased by 7.7% and is now trading at $3.24.
View the best growth stocks for 2024 here
.

Are investors shorting Aldeyra Therapeutics?

Aldeyra Therapeutics saw a decline in short interest in March. As of March 15th, there was short interest totaling 1,830,000 shares, a decline of 5.7% from the February 29th total of 1,940,000 shares. Based on an average trading volume of 544,400 shares, the days-to-cover ratio is currently 3.4 days. Currently, 3.2% of the company's shares are short sold.
View Aldeyra Therapeutics' Short Interest
.

When is Aldeyra Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ALDX earnings forecast
.

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) issued its quarterly earnings data on Wednesday, October, 27th. The biotechnology company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.01. During the same quarter in the previous year, the company posted ($0.23) earnings per share.

What ETF holds Aldeyra Therapeutics' stock?

Invesco Dorsey Wright Healthcare Momentum ETF holds 172,465 shares of ALDX stock, representing 0.81% of its portfolio.

What other stocks do shareholders of Aldeyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), KushCo (KSHB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

Who are Aldeyra Therapeutics' major shareholders?

Aldeyra Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (14.61%), Vanguard Group Inc. (6.68%), Vanguard Group Inc. (6.67%), Verition Fund Management LLC (2.25%), Dimensional Fund Advisors LP (1.77%) and Eagle Asset Management Inc. (1.72%). Insiders that own company stock include Bruce Greenberg, Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc and Todd C Brady.
View institutional ownership trends
.

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALDX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners